Literature DB >> 3110824

Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects.

D S Charney, S W Woods, W K Goodman, G R Heninger.   

Abstract

To assess the role of serotonin function in the development of panic anxiety, the behavioral and biochemical responses to the serotonin receptor agonist, m-chlorophenylpiperazine (MCPP) was examined in healthy subjects and agoraphobic and panic disorder patients. MCPP had anxiogenic effects in both the healthy subjects and patients. Panic attacks meeting DSM-III criteria occurred following MCPP in 12 of 23 patients and 6 of 19 healthy subjects (NS) and other ratings of anxiety also did not distinguish the two groups. MCPP resulted in significant but similar increases in cortisol, prolactin, and growth hormone in the healthy subjects and patients. The results of this investigation suggest that serotonin neuronal dysfunction may not be of etiologic significance in most panic disorder patients. However, the observed anxiogenic properties of MCPP suggest that additional studies of the role of serotonin systems in the pathophysiology of human anxiety disorders are indicated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110824     DOI: 10.1007/bf00215473

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  65 in total

1.  Effect of L-tryptophan and restraint stress on hypothalmic and brain serotonin turnover, and pituitary TSH and prolactin release in rats.

Authors:  G P Mueller; C P Twohy; H T Chen; J P Advis; J Meites
Journal:  Life Sci       Date:  1976-04-01       Impact factor: 5.037

2.  Catecholamine inhibition of prolactin secretion by isolated rat adenohypophyses.

Authors:  C A Birge; L S Jacobs; C T Hammer; W H Daughaday
Journal:  Endocrinology       Date:  1970-01       Impact factor: 4.736

3.  Demonstration of specific "high affinity" binding sites for [3H] imipramine on human platelets.

Authors:  S M Paul; M Rehavi; P Skolnick; F K Goodwin
Journal:  Life Sci       Date:  1980-03-24       Impact factor: 5.037

4.  Biochemical and behavioral effects of serotonin neurotoxins on the nigrostriatal dopamine system: comparison of injection sites.

Authors:  C T Giambalvo; S R Snodgrass
Journal:  Brain Res       Date:  1978-09-08       Impact factor: 3.252

5.  Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  J Clin Endocrinol Metab       Date:  1985-12       Impact factor: 5.958

6.  Serotonin function in panic disorders. The effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment.

Authors:  D S Charney; G R Heninger
Journal:  Arch Gen Psychiatry       Date:  1986-11

7.  Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).

Authors:  J A Engel; S Hjorth; K Svensson; A Carlsson; S Liljequist
Journal:  Eur J Pharmacol       Date:  1984-10-15       Impact factor: 4.432

8.  Pharmacological evidence that serotonergic stimulation of prolactin secretion is mediated via the dorsal raphe nucleus.

Authors:  L D Van de Kar; C L Bethea
Journal:  Neuroendocrinology       Date:  1982-10       Impact factor: 4.914

9.  L-5-hydroxytryptophan in the treatment of anxiety disorders.

Authors:  R S Kahn; H G Westenberg
Journal:  J Affect Disord       Date:  1985 Mar-Apr       Impact factor: 4.839

10.  Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists.

Authors:  J S Sprouse; G K Aghajanian
Journal:  Synapse       Date:  1987       Impact factor: 2.562

View more
  43 in total

1.  Landmark publications in Psychopharmacology: the first 40 years.

Authors:  K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2001-02       Impact factor: 4.530

2.  Involvement of 5-HT1B receptors in the anticonflict effect of m-CPP in rats.

Authors:  E Chojnacka-Wójcik; A Kłodzińska
Journal:  J Neural Transm Gen Sect       Date:  1992

3.  Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults.

Authors:  Roma A Vasa; Daniel S Pine; Carrie L Masten; Meena Vythilingam; Carlos Collin; Dennis S Charney; Alexander Neumeister; Karin Mogg; Brendan P Bradley; Maggie Bruck; Christopher S Monk
Journal:  Psychopharmacology (Berl)       Date:  2009-03-06       Impact factor: 4.530

4.  Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder.

Authors:  R S Kahn; G M Asnis; S Wetzler; H M van Praag
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Prospective coding of dorsal raphe reward signals by the orbitofrontal cortex.

Authors:  Jingfeng Zhou; Chunying Jia; Qiru Feng; Junhong Bao; Minmin Luo
Journal:  J Neurosci       Date:  2015-02-11       Impact factor: 6.167

Review 6.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

7.  Effects of anxiogenic drugs on the emission of 22- and 50-kHz ultrasonic vocalizations in adult rats.

Authors:  Maria Willadsen; Laura M Best; Markus Wöhr; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2018-06-16       Impact factor: 4.530

8.  5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction model.

Authors:  G A Kennett
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.

Authors:  I K Wright; M Heaton; N Upton; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus.

Authors:  P Whitton; G Curzon
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.